Jaime L. Roman Diaz,Mariola Vazquez Martinez,Farhad Khimani
Abstract:Fifty years have passed since the development of the first chemotherapy regimen for treating acute myelogenous leukemia (AML), with the approval in 1973 of the cytarabine daunorubicin (7+3) regimen. Until recently, patients diagnosed with AML had very limited treatment options and depended primarily on chemotherapy in combinations, doses, or schedules of the same drugs. Patients with advanced age, comorbidities, or relapsed or refractory disease were left with no effective options for treatment. New advances in the understanding of the biology and the molecular and genetic changes associated with leukemogenesis, as well as recent advances in drug development, have resulted in the introduction over the last few years of novel therapeutic agents and approaches to the treatment of AML as well as a new classification of the disease. In this article, we will discuss the new classification of AML; the mechanisms, actions, and indications of the new targeted therapies; the chemotherapy combinations; and the potential role of cellular therapies as new treatment options for this terrible disease.
What problem does this paper attempt to address?
The problem that this paper attempts to solve is the challenges in the field of acute myeloid leukemia (AML) treatment, especially new treatment methods beyond the traditional "7 + 3" chemotherapy regimen. The paper reviews the latest classification criteria for AML and their impact on diagnosis and treatment, and discusses in detail the emerging targeted therapeutic drugs and methods, aiming to improve the survival rate and quality of life of patients. Specifically, the paper focuses on the following aspects:
1. **New classification of AML**: The paper explores the new AML classification system based on molecular and genetic characteristics. These new classification criteria are helpful for more accurate diagnosis and prediction of patient prognosis and guiding treatment decisions.
2. **New targeted therapeutic drugs**: The paper introduces a variety of targeted therapeutic drugs developed in recent years, such as FLT3 inhibitors (e.g., midostaurin, quizartinib, gilteritinib), IDH1/2 inhibitors (e.g., ivosidenib, enasidenib), anti - CD33 monoclonal antibodies (e.g., gemtuzumab ozogamicin), etc., and their application effects in different risk groups.
3. **Treatment of elderly and frail patients**: For elderly and frail patients, the paper discusses low - intensity treatment regimens, such as the combined use of low - dose cytarabine (LDAC) with glasdegib or venetoclax, and the potential of these regimens in improving patient survival rates.
4. **Treatment of relapsed/refractory AML**: The paper also explores the treatment strategies for relapsed or refractory AML, including re - induction treatment, immunotherapy, combined use of targeted therapeutic drugs, etc., aiming to improve the remission rate and survival time of these patients.
5. **Experimental therapies**: Finally, the paper briefly introduces some experimental therapies under research, such as menin inhibitors, anti - CD47 monoclonal antibodies (magrolimab), etc. These new therapies bring hope to AML patients of certain specific subtypes.
In conclusion, through comprehensive analysis of the latest research progress, this paper aims to provide clinicians with the latest knowledge about AML treatment, promote the development of this field, and ultimately improve the treatment effect and survival quality of AML patients.